Niraparib

證據等級: L5

預測適應症: 10 個

A few things stand out in this Evidence Pack that shape how the report should read: predicted_indications[0] (rank 1, "epiglottis neoplasm") has zero supporting trials/literature despite the highest TxGNN score, original_moa is flagged [Data Gap], and taiwan_regulatory shows the drug is not marketed in New Zealand (empty license list). I'll build the report strictly from the template's instructed field (predicted_indications[0]), state data gaps honestly instead of fabricating outside knowledge, and only use context that is actually present in the JSON (e.g., trial/literature text that mentions niraparib's known ovarian cancer use) to fill the MOA/original-indication fallback language.

Niraparib: From Ovarian Cancer to Epiglottis Neoplasm

One-Sentence Summary

Niraparib is a PARP inhibitor whose established use — referenced within this evidence pack's own trial descriptions — is maintenance therapy for platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. The TxGNN model's top-ranked prediction is Epiglottis Neoplasm, but currently 0 clinical trials and 0 publications support this specific prediction — it is a model-score-only signal with no corroborating evidence.

Quick Overview

Item	Content
Original Indication	Not available from Taiwan/NZ regulatory data (drug not marketed). Based on trial descriptions within this evidence pack, niraparib's established use is maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Predicted New Indication	Epiglottis Neoplasm
TxGNN Prediction Score	99.99%
Evidence Level	L5
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for niraparib is not available (flagged as a High-severity data gap, DG002). Based on information contained elsewhere in this evidence pack (literature evidence under a different predicted indication, PMID 31466953), niraparib is described as "a poly adenosine diphosphate ribose polymerase inhibitor which uses the concept of synthetic lethality in the presence of a mutation in the breast cancer susceptibility gene (BRCA)," and is recommended as maintenance treatment for platinum-sensitive relapse of ovarian cancer. This PARP1/2 inhibition and synthetic-lethality mechanism is well established for BRCA-mutated, homologous-recombination-deficient (HRD) malignancies.

For the top-ranked prediction, epiglottis neoplasm, no mechanistic, trial, or literature evidence exists anywhere in this evidence pack. Per the model's own rationale field: epiglottis neoplasms are predominantly squamous cell carcinomas, and there is no publicly established or evidenced link between this tumor type and the BRCA/HRD pathway that underlies niraparib's synthetic-lethality mechanism. The prediction likely reflects the TxGNN model's similarity linkage to broad "neoplasm" nodes in the knowledge graph rather than a genuine, biologically grounded mechanistic signal.

It is worth noting that a lower-ranked prediction in this same evidence pack, cystic neoplasm (rank 2, score 99.99%, evidence level L2), is substantially better supported — it is anchored to high-grade serous carcinoma/BRCA-HRD biology with an active Phase 2 trial (NCT04716686, n=83, recruiting) and nine literature references. This suggests the overall TxGNN score alone is not a reliable proxy for evidence strength across ranked predictions, and epiglottis neoplasm specifically should not be advanced without independent validation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

New Zealand Market Information

Niraparib is currently not marketed in New Zealand (0 authorizations on file). No license records are available in this evidence pack.

Cytotoxicity

Niraparib is an antineoplastic agent (PARP inhibitor used in oncology, per trial/literature context in this evidence pack), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (PARP inhibitor) — based on mechanism described in literature referenced elsewhere in this evidence pack
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug-drug interaction data are currently available in this evidence pack (DDI query returned "not found"; TFDA package insert warnings/contraindications are flagged as a Blocking data gap, DG001).

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (epiglottis neoplasm) has zero supporting clinical trials or literature — this is a decision-stage S0, model-prediction-only signal (L5) with no biological or clinical corroboration. Combined with a Blocking-severity data gap on TFDA safety warnings/contraindications, this prediction cannot proceed past initial screening.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA/manufacturer package insert warnings and contraindications before any safety pre-assessment (S1) can begin
Resolve DG002 (High): obtain confirmed mechanism-of-action data from DrugBank or primary literature specific to niraparib
Independent hypothesis generation or targeted literature/trial search specifically for niraparib in epiglottis or head-and-neck neoplasms, since none currently exists
Given the disparity in evidence strength, consider prioritizing evaluation of the rank-2 candidate (cystic neoplasm, evidence level L2, active Phase 2 trial NCT04716686) instead of, or ahead of, epiglottis neoplasm
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.